Condition: Wet Age-Related Macular Degeneration (Wet AMD)
Site: The Retina Clinic London, W1G 9AY
Who this page is for
This page is for patients, optometrists, and referrers who would like an overview of the Wet AMD clinical trials currently available at The Retina Clinic London. Participation is voluntary, and suitability can only be confirmed after formal screening.
Current Wet AMD trials
We are currently identifying suitable patients for three Wet AMD clinical trials:
- One Phase 3 intravitreal gene therapy clinical trial
- One Phase 3 subretinal gene therapy clinical trial
- One Phase 1/2 intravitreal gene therapy clinical trial
These studies are investigating different gene therapy approaches in selected patients with Wet AMD. In selected patients, these approaches are being investigated as potential ways to reduce treatment burden in selected patients with Wet AMD.
As these are clinical trials, the study treatments are investigational and are only available as part of the research studies.
Who may be eligible
You may be suitable for pre-screening if:
- you are generally aged 50 years or over
- you have a confirmed diagnosis of Wet AMD within the timeframe required by a given study
- you have vision within the study range in the study eye, with minimum vision requirements in the fellow eye
- you are either treatment-naïve or have received previous anti-VEGF treatment, depending on the study
- retinal imaging shows features of active Wet AMD, such as fluid or abnormal new blood vessels
- you are able to attend screening and follow-up visits if required
Each study has different eligibility criteria. We would assess your diagnosis, imaging findings, lens status, and treatment history to advise which study may be the most appropriate for further screening.
Our current Wet AMD studies at a glance
1. Phase 3 intravitreal gene therapy clinical trial
This Phase 3 study is investigating intravitreal gene therapy in selected patients with Wet AMD.
Patients may be suitable if they are aged 50 years or over, were diagnosed with Wet AMD within the previous 6 months, and are either treatment-naïve or have received up to 3 anti-VEGF injections.
Eligibility will also depend on the full study criteria, including retinal imaging findings and other screening requirements.
2. Phase 3 subretinal gene therapy clinical trial
This Phase 3 study is investigating subretinal gene therapy in selected patients with Wet AMD.
Patients may be suitable if they are aged 50 years or over, were diagnosed with Wet AMD within the previous 4 years, are pseudophakic, and have already received anti-VEGF treatment.
3. Phase 1/2 intravitreal gene therapy clinical trial
This early-phase study is investigating intravitreal gene therapy in selected patients with Wet AMD.
Patients may be suitable if they are aged 50 years or over and were diagnosed with Wet AMD within the previous year.
Important eligibility considerations
Each study has detailed medical and eye-related eligibility criteria. Some patients may not be suitable depending on their retinal findings, previous eye treatment or surgery, lens status, or general medical history.
Suitability is assessed individually by the study team and can only be confirmed after formal screening according to the study protocol.
What happens next
If you are interested, our team can first discuss your diagnosis, imaging, and treatment history to see whether one of these trials may be suitable.
Because each study has different entry criteria, we would assess your condition and advise which study may be the most appropriate for further screening.
If appropriate, this may be followed by pre-screening and then full screening, which may include advanced retinal imaging, visual acuity assessment, and other study-specific examinations.
For optometrists and referrers
We welcome referrals for suitable adult patients with Wet AMD who may be eligible for one of our clinical trials.
Helpful referral information includes:
- diagnosis and date of diagnosis
- recent visual acuity
- OCT scans and other retinal imaging, if available
- anti-VEGF treatment history and response
- ocular surgical history
- relevant systemic medical history
Practical points
Participation is voluntary. Suitability can only be confirmed after formal screening. Pre-screening may be used where appropriate before a full study screening visit.
Next step
If you are a patient interested in finding out whether one of these studies may be suitable for you, or an optometrist wishing to discuss a possible referral, please contact The Retina Clinic London on +44 (0)20 4548 5310. Our team will be pleased to guide you through the next steps.